Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Custirsen shows no survival benefit in metastatic prostate cancer

ESMO 2016

Published: 10 Oct 2016

Views: 2827

Rating:

Save

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Prof Fizazi meets with ecancertv at ESMO 2016 to discuss the results of the AFFINITY trial of custirsen, a clusterin upstream inhibitor which had previous indications of improved clinical outcomes for castration resistant prostate cancer.

He describes the results from the AFFINITY trial as failing to reach significant difference in overall survival, and considers future paths for clusterin-targeted cancer therapy.

Prof Fizazi presented these results to the conference, and news coverage of this story is available here.

Related Videos

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

Choosing Wisely in pathology

Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in pathology ( Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC...

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

More from ecancer